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sion was used to estimate the odds ratio of the outcome events for patients whose 
treatment in the week before event date included statins and BBs as compared to 
patients whose treatment included statins and other BPLD(s). Results: Patients on 
statins and BBs showed substantially higher risks for cardiovascular death (OR= 2.12, 
95%CI: 1.81–2.49), all-cause death (OR= 1.64, 95%CI: 1.49–1.81), CVD events (OR= 1.96, 
95%CI: 1.80–2.12) and hospitalization for CVD (OR= 1.99, 95%CI: 1.82–2.17) as com-
pared to patients on statins and other BPLDs. Sensitivity analyses suggest that this 
higher risk is not due to differences in prescription patterns based on perceived 
disease severity (indication bias). ConClusions: In elderly hypertensive patients, 
the concurrent use of statins and BBs is associated with less effective primary 
prevention in comparison to the use of statins in combination with other BPLDs. 
Consequently, the difference observed in the efficacy of different classes of BPLDs 
in elderly populations in primary prevention remains significant in the subpopula-
tion receiving statins. Further studies should be conducted to confirm this finding.
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objeCtives: We examined the potential clinical implications of prescribing pat-
terns of generic statins within 11 Latin American markets (LA11). In LA11, generic 
versions of pravastatin, simvastatin and atorvastatin are available, however, each 
statin has a different LDL-cholesterol (LDL-C) lowering efficacy that may ulti-
mately result in differences in the incidence of CV events. 2011 LA11 prescription 
data indicate that statins are prescribed at doses that do not yield equivalent 
LDL-C lowering. Thus we calculated the weighted average daily doses (WADDs) 
of pravastatin, simvastatin and atorvastatin within LA11 and estimated the aver-
age LDL lowering with each statin, and the incidence of CV events. Methods: 
The WADDs of prescribed simvastatin, pravastatin and atorvastatin in LA11 were 
derived from IMS data. The LDL-C modifying potencies of the WADDs were inter-
polated from dose response curves from Nicholls et al (Am J Cardiol, 2010), and 
Law et al (BMJ, 2003). The relationship between LDL-C reduction and the result-
ant impact on cardiovascular events was derived from the Cholesterol Treatment 
Trialists’ Collaboration (CTTC, Lancet 2010), where a 1mmol/L reduction in 
LDL-C, translated to a 22% reduction in major cardiovascular events. Results: 
Across LA11, the WADDs for pravastatin, simvastatin and atorvastatin were 
24.9mg, 22.4mg and 20.6mg, respectively. The corresponding reductions in LDL-C 
at these doses were estimated to be 25.0%, 33.4% and 40.6%. Assuming a pre-
treatment LDL-C of 4.0mmol/L, these lipid changes would lead to reductions 
in the risk of a major coronary/stroke event of 22.0%, 29.4% and 35.8%, respec-
tively. ConClusions: At currently prescribed WADDs in LA11, the real world 
use of atorvastatin provides a superior reduction in LDL-C to either simvastatin 
or pravastatin, and hence would be expected to result in a greater reduction in 
cardiovascular events.
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objeCtives: Diuretics are drugs of first choice in the treatment of hypertension. 
The aim of this study was to analyze the consumption of diuretics in Serbia in the 
period from 2006 to 2010 year. Methods: The data about the use of drugs were 
taken from the Agency for Drugs and Medical Devices of the Serbia. Results: The 
use of diuretics during the observed period in Serbia is quite small and it ranged 
from 5 to 6% of the total consumption of all drugs from the C group. Furosemide 
was the most frequently used diuretic. In the five year period furosemide con-
sumption ranged from 33-55% of the total consumption of all diuretics. The second 
largest consupmtion during first four years of the study was that of indapamide. 
Indapamide consumption in the fifth year was at the fourth position. At the third 
position in drug consumption in the first four years was hydrochlorothiazide. Use 
of hydrochlorothiazide in 2010 took second place. Spironolactone has occupied 
the fourth position in the first four years. During the last years of the period 
spironolactone occupied the third position. Consumption of all other diuretics 
was small and it was only a few percent of the total consumption of all diuret-
ics. ConClusions: In Serbia, in the observed period, consumption of diuterics 
is two to three times lower in comparison with the consumption of diuretics 
in Norway and Finland. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science, Republic of Serbia, pro-
ject no 41012.
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objeCtives: Drugs of first choice in the treatment of hypertension are: β -blockers, 
tiazide diuretics, ACE inhibitors, angiotensin receptor inhibitors and Ca chan-
nel blockers. The aim of this study was to analyze the consumption of antihy-
pertensive drugs in Serbia in the period from 2007 to 2011 year. Methods: The 
data about the use of drugs were taken from the Agency for Drugs and Medical 
Devices of the Serbia. Results: The use of diuretics during the observed period 
in Serbia is quite small and it ranged from 5 to 6% of the total consumption of all 
drugs from the C group. Consumption of β -blockers was around 12% during all 5 
years. Consumption of calcium channel blockers was less than 12% of the total 
consumption of all drugs from group C in the first 2 years of the observed period. 
However, consumption of such drugs in the last 3 years growing over 18% of the 
tors of a difficult procedure. ConClusions: Factors influencing the difficulty of 
an extraction procedure are the number of leads, the presence of screw leads, the 
presence of dual-coil tachy leads, the years since the oldest lead was implanted and 
the absence of leads with vegetation.
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objeCtivos: El Euroscore(EU) es el modelo predictivo más usado en cirugía cardi-
aca; sin embargo, sobreestima el riesgo y la información necesaria para calcularlo 
no siempre está disponible. Este estudio fue diseñado para: 1). Definir si adicio-
nar el valor preoperatorio de hemoglobina (HB), péptido natriurético tipo B(BNP) o 
ambos, al EU, mejoran su capacidad predictiva sobre morbimortalidad a 6 meses 
de seguimiento postoperatorio en toda la muestra y en los pacientes diabéticos; y 
2). Evaluar la utilidad de EU en nuestro medio. MetodologíAs: Se incluyeron 492 
pacientes quirúrgicos cardiacos. Se comparò directamente la capacidad predictiva 
de BNP y/o HB vs EU. Luego se evaluó en que tanto la incorporación de BNP y/o HB 
al EU, adicionaron en términos de lograr mejor discriminación. Para cada uno de 
los desenlaces se construyeron y compararon curvas ROC. ResultAdos: Sobre 
mortalidad, BNP o HB no adicionan capacidad predictiva al EU ni en la muestra 
global ni en diabéticos. La mortalidad intrahospitalaria fue mejor discriminada 
por EU aislado: área bajo la curva ROC (ABC-ROC): 0.83(IC95%0.75-0.92) y a 6 meses, 
ABC-ROC 0.73 (IC95% 0.64-0.83); en pacientes diabéticos, ABC-ROC 0.95 (IC95%0.91-
1.00) para mortalidad intrahospitalaria y a 6 meses, ABC-ROC 0.84 (IC95% 0.74-0.98). 
La discriminación obtenida con BNP fue buena para bajo gasto cardiaco: ABC-ROC, 
0.72 (IC95% 0.67-0.77); e insuficiencia renal aguda ABC-ROC 0.75 (IC95% 0.76-0.84). 
Los mejores predictores de transfusión fueron EU+HB ó BNP+HB. EU mostró buena 
capacidad predictiva (ABC-ROC≥ 0.70) sobre morbilidad combinada, estancia pro-
longada en cuidado intensivo, bajo gasto cardiaco e insuficiencia renal y a 6 meses 
en la discriminación de evento cerebrovascular, tanto en el grupo total como en 
diabéticos. ConClusiones: La capacidad discriminatoria de EU para mortalidad 
en nuestro medio es muy buena, especialmente en diabéticos. BNP o HB no adi-
cionan capacidad predictiva. En la mayor parte de los desenlaces de morbilidad la 
discriminación obtenida con BNP aislado es comparable a EU.
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objeCtives: To compare changes in blood pressure after 8 weeks of therapy 
between a fixed-dose combination (FDC) of amlodipine/losartan and amlodipine/
valsartan using a network meta-analysis because there are no trials directly compar-
ing amlodipine/losartan to amlodipine/valsartan. Methods: A systematic search 
identified six randomized controlled trials of study FDCs and their component 
monotherapies; 3 included amlodipine/losartan and 3 included amlodipine/vals-
artan. Conventional fixed-effects methods were used to conduct the comparisons. 
The change in sitting diastolic and systolic blood pressure (sitDBP, sitSBP) at 8 weeks 
post-randomization was the primary and secondary effect measures. Results: 
Amlodipine/losartan 5/50 mg produced greater reductions in sitDBP (-1.27 mmHg, 
95% confidence interval (CI) -5.7 - 2.2) and sitSBP (-3.7 mmHg, 95% CI -9.0 - 2.9) than 
amlodipine/valsartan 5/80 mg. Amlodipine/losartan 5/100 mg produced a greater 
reduction in sitDBP (-0.45 mmHg, 95% CI -3.7 - 2.7) than amlodipine/valsartan 5/160 
mg while amlodipine/valsartan 5/160 mg had a greater reduction in sitSBP (0.2 
mmHg, 95% CI -6.2 - 6.0) than amlodipine/losartan 5/100 mg. The confidence of supe-
rior antihypertensive efficacy for COZAAR XQ 5/50 mg than amlodipine/valsartan 
5/80 mg is 77% for sitDBP and 89% for sitSBP, while the confidence of greater efficacy 
for amlodipine/losartan 5/100 mg than amlodipine/valsartan 5/160 mg is 61% for 
sitDBP and 48% for sitSBP. With 95% CI, the reduction difference in sitDBP and sitSBP 
between amlodipine/valsartan 5/80 mg and amlodipine/losartan 5/100 mg is not 
expected to exceed 1.6 mmHg and 1.26 mmHg, respectively, and not expected to 
exceed 2.31 mmHg and 5.38 mmHg, respectively with amlodipine/valsartan 5/160 
mg versus amlodipine/losartan 5/100 mg. ConClusions: The blood pressure low-
ering effect with amlodipine/losartan and amlodipine/valsartan was comparable. 
The findings from this network metaanalysis do not indicate a potential superiority 
of the reductions realized with amlodipine/valsarta relative to amlodipine/losartan.
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objeCtives: Differences in efficacy of different classes of blood pressure lowering 
drugs (BPLDs) have been observed in elderly primary prevention populations, with 
beta-blockers (BBs) reported to be less efficacious for primary prevention. In this 
study, we assessed if these differences remained significant in patients that use 
statins concurrently. Methods: We conducted a series of population-based nested 
case-control studies using administrative data from 104,023 diagnosed hypertensive 
patients without recent antecedents of diabetes or cardiovascular disease (CVD) in 
the province of Quebec (Canada) between 2000 and 2004. Follow-up ended either 
with an outcome event, or at the end of 2009. Individuals with an outcome event (all-
cause death, CVD event) were considered cases. Controls were matched according 
to age, sex, date of cohort entry, and comorbidity index. Conditional logistic regres-
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tal budget impact with this new procedure incorporation under the SUS perspec-
tive. Methods: The BIA was based on a Markov model with quarterly cycles and 
5-year time horizon in order to predict clinical and economic outcomes in a scenario 
with TAVI incorporation compared to the actual scenario – drug therapy (amiodarone, 
furosemide and digoxin) with or without aortic balloon valvoplasty. Epidemiological 
data were obtained from DATASUS and survival was extrapolated from PARTNER 
cohort B trial by using a Weibull distribution. Resource use, also gathered from this 
trial, included early perioperative complications (30 days) and late events (rehospi-
talization, dialysis, stroke, pacemaker implantation and major vascular complica-
tions). Costs were taken from the official Brazilian public official lists (DATASUS and 
BPS). Market-share data was obtained from Sociedade Brasileira de Hemodinâmica e 
Cardiologia Intervencionista. Results: The estimated number of Brazilian patients 
eligible for SSVS treatment was 795, 922, 1,180, 1,335 and 1,402 respectively for years 1-5 
of analysis. Compared to the current scenario, the inclusion of TAVI procedure with a 
13% market share during the analysis period shows an additional budget through year 
1-5 of 3.5M, 5.0M, 6.7M, 8.1M and 9.4M, consecutively. ConClusions: The incremental 
budget impact to include TAVI as a treatment option in the Brazilian Public Healthcare 
System for SSVS high-risk patients was estimated to be USD 65 million in 5 years.
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INC, Rio de Janeiro, Brazil
objetivos: Analisar o impacto orçamentário do implante de oclusor septal per-
cutâneo para o fechamento de comunicação interatrial do tipo ostium secundumem 
comparação a cirurgia cardíaca convencional. Métodos: Análise sob a perspectiva 
do Sistema Único de Saúde (SUS) em um horizonte temporal de cinco anos, para 
uma população de pacientes portadores de CIA do tipo Ostium Secundum.O modelo 
considerou os custos com as intervenções durante o período de internação e a 
análise da incorporação do oclusor seguiu o pressuposto de uma taxa de utilização 
de 75% dos pacientes portadores de CIA OS. ResultAdos: Apresentou uma redução 
de mais de sete milhões de reais a favor da incorporação do oclusor percutâneo 
em relação a cirurgia como procedimento exclusivo. As análises de sensibilidade 
confirmaram uma economia favorecendo o oclusor percutâneo para o fechamento 
de CIA ostium secundum. E ao cruzar as variações de custos da cirurgia, do oclusor 
e das taxas de utilização para uma melhor aproximação da realidade, o resultado 
permaneceu favorável e demonstrou uma concentração do número de casos na 
faixa entre zero e R$40.000.000,00 em economia. ConClusões: A análise demon-
strou a possibilidade de redução dos custos para o fechamento de CIA do tipo ostium 
secundumcom a incorporação de uma tecnologia que já vem sendo bem indicada 
e utilizada ao longo dos últimos 36 anos, como uma alternativa segura e eficaz ao 
fechamento cirúrgico tradicional. O implante de oclusor septal percutâneo é uma 
opção repleta de méritos ao evitar que o paciente sofra os traumas físicos e riscos 
associados ao procedimento cirúrgico, bem como os riscos psicológicos causados 
pela estética gerada pela cicatriz cirúrgica e trauma da internação para as crianças.
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objeCtives: To develop cost-effectiveness analysis of collagenase (CO) versus 
hydrogel (HG) dressings for chronic-wound treatment in adults, under the per-
spective of Brazilian public payers. Methods: Data from the Brazilian Hospital 
Information System from January 1st to December 31st 2012 was used to deﬁne the 
annual number of hospital admissions due to chronic wounds (only non-surgical 
records with L89 ICD-10 code included). The model assumed that CO is the current 
practice in Brazilian public hospitals and patients are discharged at the time their 
wound heals. The difference in MHT was applied to the average length of stay 
(LOS) reported in the database. Resource use was estimated through expert panel 
and unit costs were obtained from Brazilian ofﬁcial price lists. Results: A total 
of 280,440 hospitalizations were identiﬁed with mean LOS of 4.47 days. The model 
estimated costs for the inpatient period assuming one dressing change for CO and 
HG. The cost per dressing change was estimated as 13.83BRL for CO and 11.95BRL 
for HG and the overall treatment costs were 61.82BRL and 53.42BRL according to the 
LOS. HG-related incremental costs were -8,40BRL indicating a cost-saving proﬁle. 
Addopting HG as wound management protocol would save 527,227.20BRL for the 
2012 cohort. Beneﬁts in terms of reduction in LOS were not accounted in the base 
case scenario. ConClusions: HG dressing has shown higher efﬁcacy when com-
pared to CO dressings, with fewer costs. The clinical and economic incremental 
results between different dressings reinforce the need of evidence-based decision 
making and rational resource allocation.
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objeCtives: The present study determined the total direct health-care costs for the 
management of PAH patients with differing degrees of disease severity. The study 
also aimed to find the key cost drivers in the management of PAH. Methods: PAH 
patients were recruited from a tertiary care hospital between January 1, 2009 and 
total consumption of all drugs from the C group. Total consumption of drugs acting 
on the renin-angiotensin system (C09) in Serbia in opserved period was over 41 
% of the total consumption of all drugs from the C group. The highest percentage 
in this group belonged to the ACE inhibitors. Consumption of angiotensin recep-
tor inhibitors is small and it is only a few percent of the total consumption of all 
drugs from C09 group. However, consumption of drugs in this subgroup recorded 
steady growth in recent years. ConClusions: In Serbia in the observed period, 
ACE inhibitors are the most frequently used drugs within the group of drugs which 
is used for treatment of hypertension. This research was supported by Provincial 
Secretariat for Science and Technological Development, Autonomous Province of 
Vojvodina project No 114-451-2458/2011 and by Ministry of Science, Republic of 
Serbia, project no 41012.
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objeCtivos: Estimar el impacto en discapacidad y económico del incremento de 
utilización de trombolisis para el manejo agudo de ictus isquémico (IS) en Chile, 
aplicando un modelo de simulación de eventos discretos. MetodologíAs: Se mod-
eló la historia natural y el manejo agudo de los IS para población adulta chilena, 
incorporando tiempos desde el inicio de síntomas al tratamiento y cuatro escenarios 
de utilización de trombolisis: a) utilización actual (1,7%), b) utilización de 11,6% 
tratando todos los pacientes que son atendidos dentro de la ventana terapéutica, 
c) 25% de utilización, y d) 100% de utilización. Se usaron distribuciones empíricas 
y teóricas para incluir la probabilidad y tiempos de los eventos. Se realizó una 
simulación entre 2002-2017, usando el software ARENA. Los resultados fueron la 
prevalencia de discapacidad por escenario. Se realizó un análisis de impacto pre-
supuestario desde la perspectiva del asegurador público de salud, considerando los 
costos directos del tratamiento y de rehabilitación. ResultAdos: En 2017 man-
teniendo la actual utilización de trombolisis (1,7%), la tasa de prevalencia por IS es 
360,8 por 100.000 habitantes, presentando una disminución entre los escenarios, 
siendo 299,8 cuando todos los pacientes son tratados. Con respecto a la utilización 
actual, aumentar el tratamiento al 11,6% evita 779 discapacitados, al 25% evita 
1.783 y tratar a todos los pacientes evita 8.534. A lo largo de la simulación, los costos 
ahorrados por casos de rehabilitación evitados son más bajos que los costos de la 
trombolisis. ConClusiones: La tasa de prevalencia de discapacidad disminuye 
moderadamente al incrementar la utilización de trombolisis. El impacto poblacional 
en discapacidad manteniendo la utilización actual es marginal, siendo recomenda-
ble incrementar su utilización. Los costos directos aumentarían por sobre el costo de 
rehabilitación evitados, sin embargo, es necesario considerar la limitada cobertura 
de atención de la discapacidad en Chile y los costos sociales.
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objeCtives: There is no enough data available in our country about the preva-
lence of risk factors for ST elevation myocardial infarction (STEMI) and which has 
the highest mortality rate in hospitals of Pakistan. The purpose of study was to 
access the age distribution, location of infarct, risk factors, sign & symptoms and 
in-hospital management of STEMI patients in Bahawalpur region, southern Punjab, 
on of the regions with high risk of coronary heart disease. Methods: A retrospec-
tive study of 400 patients diagnosed as STEMI admitted to Bahawal Victoria Hospital 
(BVH), Bahawalpur, Southern Punjab, Pakistan was done by following their hospital 
record. Results: The mean age of STEMI patients were 40 ±10. Smoking, Diabetes 
and Hypertension were the risk factors (51.5%), (28%), (20.5%) respectively. Anterior 
wall Myocardial infarctions were seen (51.5%). Sweating, vomiting, shortness of 
breath (SOB) & nausea accounted for more than 60% of the symptoms with chest 
pain mostly in left arm. Among the patients who reached early to hospital & received 
Streptokinase (SK) were 150 (75%), those late for SK were 44(22%), thrombolytic 
therapy was contraindicated only in 6 (3%) patients. Most prescribed medication 
are aspirin (100%), clopidogrel (98%), statin (96%), ACE-I (77.5%), nitrates (69.5%), 
beta blocker (60%), anticoagulant (50%), LMW-heparin (33 %). ConClusions: The 
result of our study, in which the risk factors especially smoking were found to have 
a prevalence in patients with STEM1 living in southern Punjab, suggested that STEM 
1 can be prevented by the modification of these risk factors.
CArDioVAsCulAr DisorDers – Cost studies
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A buDget imPACt AnAlysis (biA) of trAnsCAtheter AortiC VAlVe 
imPlAntAtion (tAVi) in high-risk PAtients With syntomAtiC seVere 
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objeCtives: Aortic valve stenosis is a progressive valvular heart disease with a stand-
ard care that involves a major open surgery. However, part of the patients is ineligible 
for surgery, therefore drug therapy is the only option available. Once TAVI is a less 
invasive surgical option, clinical trials demonstrated significant benefits, although 
procedure and device are costly. The aim of this study was to estimate the incremen-
